Aurobindo Pharma in Pole Position for $5.5 Billion Zentiva Buyout

Indian pharmaceutical major Aurobindo Pharma has emerged as the front-runner to acquire Zentiva, the Czech-based generic drugmaker owned by Advent International, in a deal that could be valued at $5.5 billion, according to reports from The Economic Times.

If finalized, this would mark the largest overseas acquisition ever by an Indian pharma company, cementing Aurobindo’s position among the top global players in the generics and biosimilars space.

Current Status of the Deal

Aurobindo clarified in an exchange filing that no binding agreement has been signed yet, underscoring that negotiations remain ongoing. Markets reacted cautiously, with Aurobindo shares sliding as much as 4.7% intraday, before settling down about 3.7%.

Strategic Rationale

Financing the Buyout

Reports suggest Aurobindo has secured a $4.75 billion bridge loan from MUFG Bank, with the remainder—around $800 million—to be funded through internal resources. This mix highlights the ambitious scale of the potential transaction and the company’s appetite for global expansion.

Investor Perspective

While the acquisition promises to elevate Aurobindo into a higher league of global generics and biosimilar players, investor caution is evident: